CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)	Total	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit Prior to Exploration Stage [Member]	Accumulated Deficit During Exploration Stage [Member]
Balance at Dec. 31, 2020	$ (47,829,437)	$ 183,939	$ 128	$ 74,008,636	$ (20,009,496)	$ (102,012,644)
Balance (in shares) at Dec. 31, 2020		183,938,549	128,000
Shares issued for conversion of Series B Preferred Stock	$ 7,680	$ 6,167	$ (128)	1,641
Shares issued for conversion of Series B Preferred Stock (in shares)		6,167,273	(128,000)
Shares issued as part of settlement of liability (in shares)		1,162,791
Issuance of shares for debt issuance cost		$ 58,140
Issuance of shares of common stock for consulting services (in shares)	9,528,689	3,836,475
Shares issued in private placement	$ 185,000		$ 176	184,824
Shares issued in private placement (in shares)			176,136
Beneficial conversion feature on Series B Preferred Stock	112,612			112,612
Deemed dividend from beneficial conversion feature on Series B Preferred Stock	(112,612)			(112,612)
Shares issued upon cashless exercise of options		$ 3,836		(3,836)
Shares issued upon cashless exercise of options (in shares)		3,836,475
Shares issued for employee bonus	58,140	$ 1,163		56,977
Shares issued for employee bonus (in shares)		1,162,791
Stock option compensation expense	7,886			7,886
Net Loss	(1,681,151)					(1,681,151)
Balance at Jun. 30, 2021	(49,251,882)	$ 195,105	$ 176	74,256,128	(20,009,496)	(103,693,795)
Balance (in shares) at Jun. 30, 2021		195,105,088	176,136
Balance at Mar. 31, 2021	(48,505,632)	$ 195,105	$ 95	74,167,266	(20,009,496)	(102,858,602)
Balance (in shares) at Mar. 31, 2021		195,105,088	95,000
Shares issued in private placement	85,000		$ 81	84,919
Shares issued in private placement (in shares)			81,136
Beneficial conversion feature on Series B Preferred Stock	51,874			51,874
Deemed dividend from beneficial conversion feature on Series B Preferred Stock	(51,874)			(51,874)
Stock option compensation expense	3,943			3,943
Net Loss	(835,193)					(835,193)
Balance at Jun. 30, 2021	(49,251,882)	$ 195,105	$ 176	74,256,128	(20,009,496)	(103,693,795)
Balance (in shares) at Jun. 30, 2021		195,105,088	176,136
Balance at Dec. 31, 2021	$ (50,400,882)	$ 217,654	$ 262	74,686,581	(20,009,496)	(105,295,883)
Balance (in shares) at Dec. 31, 2021		217,655,150	262,000
Shares issued for conversion of Series B Preferred Stock		$ 53,388	$ (176)	(53,212)
Shares issued for conversion of Series B Preferred Stock (in shares)	20,164,153	53,387,788	(176,000)
Shares issued as part of settlement of liability	$ 53,778	$ 4,444		49,334
Shares issued as part of settlement of liability (in shares)		4,444,444
Issuance of shares for debt issuance cost	1,740	$ 300		1,440
Issuance of shares for debt issuance cost (in shares)		300,000
Issuance of shares of common stock for consulting services	70,000	$ 10,000		60,000
Issuance of shares of common stock for consulting services (in shares)		10,000,000
Beneficial conversion feature on Series B Preferred Stock	25,947			25,947
Deemed dividend from beneficial conversion feature on Series B Preferred Stock	(25,947)			(25,947)
Shares of Series B Preferred Stock issued to Geneva Roth	$ 75,000		$ 78	74,922
Shares of Series B Preferred Stock issued to Geneva Roth (in shares)			78,000
Shares issued upon cashless exercise of options (in shares)	0
Stock option compensation expense	$ 42,422			42,422
Net Loss	(1,889,461)					(1,889,461)
Balance at Jun. 30, 2022	(52,047,403)	$ 285,786	$ 164	74,861,487	(20,009,496)	(107,185,344)
Balance (in shares) at Jun. 30, 2022		285,787,382	164,000
Balance at Mar. 31, 2022	(51,369,818)	$ 252,562	$ 187	74,798,477	(20,009,496)	(106,411,548)
Balance (in shares) at Mar. 31, 2022		252,563,747	187,000
Shares issued for conversion of Series B Preferred Stock		$ 33,224	$ (101)	(33,123)
Shares issued for conversion of Series B Preferred Stock (in shares)		33,223,635	(101,000)
Beneficial conversion feature on Series B Preferred Stock	25,947			25,947
Deemed dividend from beneficial conversion feature on Series B Preferred Stock	(25,947)			(25,947)
Shares of Series B Preferred Stock issued to Geneva Roth	75,000		$ 78	74,922
Shares of Series B Preferred Stock issued to Geneva Roth (in shares)			78,000
Stock option compensation expense	21,211			21,211
Net Loss	(773,796)					(773,796)
Balance at Jun. 30, 2022	$ (52,047,403)	$ 285,786	$ 164	$ 74,861,487	$ (20,009,496)	$ (107,185,344)
Balance (in shares) at Jun. 30, 2022		285,787,382	164,000